ASCO Annual Meeting
ASCO Annual Meeting
August 08, 2017
2 min read

Resuming treatment with cabazitaxel provides ‘option’ in advanced prostate cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CHICAGO – Retreatment with cabazitaxel demonstrated encouraging activity and acceptable toxicity when used in combination with a new hormonal therapy and docetaxel among men with heavily pretreated, metastatic, castration-resistant prostate cancer, according to findings presented at the ASCO Annual Meeting.

“Only two chemotherapies have shown an OS benefit in metastatic, castration-resistant prostate cancer: docetaxel and cabazitaxel,” the researchers wrote. “In patients previously treated with a new hormonal therapy (enzalutamide or abiraterone), docetaxel and cabazitaxel, therapeutic options are limited.”

Constance Thibault, MD, of the Georges Pompidou European Hospital in Paris, and colleagues performed a retrospective study in patients with metastatic, castration-resistant prostate cancer. Enrollment required prior treatment with docetaxel, cabazitaxel and a novel hormonal therapy (enzalutamide or abiraterone), as well as a positive response to cabazitaxel. The researchers examined the records of 70 patients from 17 centers in France, Italy, the United Kingdom and Austria.

Most patients (n = 52) were treated with docetaxel first, followed by a new hormonal therapy and then cabazitaxel. An additional 15 patients received docetaxel first, but were treated with cabazitaxel second and a new hormonal therapy last. The remaining 3 patients were treated with a new hormonal therapy first, followed by docetaxel and then cabazitaxel.

When treatment with cabazitaxel resumed, high-volume disease was reported in most patients (83%) and 10% had visceral metastases. Narcotic analgesics had been prescribed for 66% of patients and the majority (68%) had an ECOG performance status of zero to one. The median neutrophil-to-lymphocyte ratio was 3.1.

Treatment with cabazitaxel was reinstituted for a median number of 6 cycles, with a median duration of 8.6 months since the last cycle of cabazitaxel. Most patients (59%) received 25 mg/m2 every 3 weeks; 27% were treated with 20 mg/m2 every 3 weeks and 11% of patients received 16 mg/m2 every 3 weeks. Prophylactic treatment with granulocyte colony-stimulating factor was administered to 47% of patients.

Median PFS was 11.3 months among patients treated with docetaxel, 12 months among patients who received a novel hormone therapy, 11.9 months after initial treatment with cabazitaxel (median number of cycles = 8) and 7.8 months after resuming treatment. Median OS “calculated from the first life-extending therapy was 59.9 months (95% CI, 47.8-66.4),” the researchers wrote.

The toxicities after reinstituting treatment were reported to be tolerable; 7 patients (10%) experienced grade 3-4 neutropenia.

“Cabazitaxel rechallenge might be an option in heavily treated patients still fit to receive chemotherapy,” the researchers wrote. – by Julia Ernst, MS


Thibault C, et al. Abstract 5033. Presented at: ASCO Annual Meeting: June 2-6, 2017; Chicago.

Disclosures: Thibault reports that she serves as a consultant or adviser for Novartis and Sanofi and that she receives travel, accommodations and expenses from Novartis and Sanofi. Please see the full study for a list of all other researchers’ relevant financial disclosures.